



US008163723B2

(12) **United States Patent**
Lulla et al.(10) **Patent No.:** **US 8,163,723 B2**
(45) **Date of Patent:** **Apr. 24, 2012**(54) **COMBINATION OF AZELASTINE AND STEROIDS**(75) Inventors: **Amar Lulla**, Mumbai (IN); **Geena Malhotra**, Mumbai (IN)(73) Assignee: **CIPLA Limited**, Mumbai (IN)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 77 days.

(21) Appl. No.: **12/879,515**(22) Filed: **Sep. 10, 2010**(65) **Prior Publication Data**

US 2010/0331289 A1 Dec. 30, 2010

Related U.S. Application Data

(62) Division of application No. 10/518,016, filed as application No. PCT/GB03/02557 on Jun. 13, 2003.

(30) **Foreign Application Priority Data**

Jun. 14, 2002 (GB) 0213739.6

(51) **Int. Cl.**
A61K 31/55 (2006.01)(52) **U.S. Cl.** **514/171**(58) **Field of Classification Search** None
See application file for complete search history.(56) **References Cited****U.S. PATENT DOCUMENTS**

2,837,464 A 6/1958 Nobile
 3,067,197 A 12/1962 Agnello et al.
 3,312,590 A 4/1967 Elks et al.
 3,506,694 A 4/1970 Oxley
 3,557,162 A 1/1971 Voorschoten et al.
 3,639,434 A 2/1972 Oxley et al.
 3,755,302 A 8/1973 Ercoli et al.
 3,828,080 A 8/1974 May et al.
 3,856,828 A 12/1974 Phillipps et al.
 3,891,631 A 6/1975 Phillipps et al.
 3,981,894 A 9/1976 Phillipps et al.
 3,989,686 A 11/1976 Phillipps et al.
 4,093,721 A 6/1978 Phillipps et al.
 4,113,680 A 9/1978 Kamano et al.
 4,187,301 A 2/1980 Edwards
 4,188,385 A 2/1980 Edwards
 4,198,403 A 4/1980 Alvarez
 4,221,787 A 9/1980 Bodor et al.
 4,261,984 A 4/1981 Alvarez
 4,263,289 A 4/1981 Edwards
 4,267,173 A 5/1981 Draper
 4,285,937 A 8/1981 Kalvoda
 4,310,466 A 1/1982 Edwards
 4,335,121 A 6/1982 Phillipps et al.
 4,377,575 A 3/1983 Stache et al.
 4,472,393 A 9/1984 Shapiro

4,607,028 A 8/1986 Schmidlin
 4,710,495 A 12/1987 Bodor
 4,861,765 A 8/1989 Mitsukuchi et al.
 4,992,474 A 2/1991 Skidmore et al.
 4,994,439 A 2/1991 Longnecker et al.
 4,996,335 A 2/1991 Bodor
 5,063,222 A 11/1991 Komoto et al.
 5,081,113 A 1/1992 Claussner et al.
 5,164,194 A 11/1992 Hettche
 5,202,316 A 4/1993 Claussner et al.
 5,232,919 A 8/1993 Scheffler et al.
 5,271,946 A 12/1993 Hettche
 5,362,721 A 11/1994 Stache et al.
 5,420,120 A 5/1995 Boltralik
 5,608,093 A 3/1997 Stache et al.
 5,658,549 A 8/1997 Akehurst et al.
 5,658,919 A 8/1997 Ratnaraj et al.
 5,707,984 A 1/1998 Tjoeng et al.
 5,837,699 A 11/1998 Sequeira et al.
 5,849,265 A 12/1998 Li-Bovet et al.
 5,889,015 A 3/1999 Sequeira et al.
 5,914,122 A 6/1999 Otterbeck et al.
 5,972,920 A 10/1999 Seidel
 5,981,517 A 11/1999 Bodor
 6,017,963 A 1/2000 Alfonso et al.
 6,057,307 A 5/2000 Sequeira et al.
 6,127,353 A 10/2000 Yuen et al.
 6,136,294 A 10/2000 Adjei et al.
 6,197,761 B1 3/2001 Biggadike et al.
 6,261,539 B1 7/2001 Adjei et al.
 6,294,153 B1 9/2001 Modi
 6,319,513 B1 11/2001 Dobrozsi
 6,330,938 B1 12/2001 Herve et al.
 6,391,340 B1 5/2002 Malmqvist-Granlund et al.
 6,395,300 B1 5/2002 Straub et al.
 6,416,743 B1 7/2002 Fassberg et al.
 6,525,228 B2 2/2003 Chauvin et al.

(Continued)

FOREIGN PATENT DOCUMENTS

AU 2003244799 B2 12/2003

(Continued)

OTHER PUBLICATIONS

Office Action (Final) dated Feb. 18, 2011 (23 pages), U.S. Appl. No. 12/508,388, filed Jul. 23, 2009.

(Continued)

Primary Examiner — Johann Richter*Assistant Examiner* — Thor Nielsen(74) *Attorney, Agent, or Firm* — Conley Rose, P.C.; Rodney B. Carroll(57) **ABSTRACT**

A pharmaceutical product or formulation, which comprises azelastine or a pharmaceutically acceptable salt, solvate or physiologically functional derivative thereof, and a steroid, or a pharmaceutical acceptable salt, solvate or physiologically functional derivative thereof, preferably the product or formulation being in a form suitable for nasal or ocular administration.

28 Claims, No Drawings